- Home
- DTIL vs CGEN Comparison
DTIL vs CGEN Comparison
Compare DTIL & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | CGEN |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.7M | 191.1M |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | DTIL | CGEN |
|---|---|---|
| Price | $7.29 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $45.00 | $5.00 |
| AVG Volume (30 Days) | ★ 632.2K | 251.2K |
| Earning Date | 05-14-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $1.30 |
| 52 Week High | $9.62 | $3.24 |
Technical Indicators
Market Signals| Indicator | DTIL | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 47.52 |
| Support Level | $6.30 | $2.22 |
| Resistance Level | $7.96 | $2.35 |
| Average True Range (ATR) | 0.62 | 0.11 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 11.37 | 16.18 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.